22 Nov
  • By Alicia Clough
  • Cause in

Even More to Be Thankful For This Thanksgiving

When Thanksgiving comes around each year, I’m reminded of how much we actually have to be thankful for. As a Duchenne parent, I am thankful every day for the moments I get to spend with my son Hawken. On Thanksgiving, I am thankful for all those who continue to fight alongside us for a cure […]

READ MORE
08 Nov
  • By Alicia Clough
  • Cause in

CureDuchenne Ventures Seed Funding to Exonics Helped Advance CRISPR Research and Attract Series A Financing to Accelerate Development of Lead Gene Editing Program in Duchenne

Dr. Eric Olson to Provide CRISPR/Cas9 and Gene Therapy Update During November 16 Webinar   We are delighted that Exonics Therapeutics has closed a $40 million Series A financing with The Column Group (TCG) to advance its lead SingleCut CRISPR gene editing program in Duchenne muscular dystrophy and potentially other neuromuscular diseases.  CureDuchenne Ventures helped […]

READ MORE
03 Nov
  • By Alicia Clough
  • Cause in

Sibling Saturday: Finding Inspiration in All Shapes and Sizes

No matter how long we live, the ones who will have known us the longest are our siblings.  For siblings Wil and Emily Cook, the time they have together is more precious knowing Duchenne muscular dystrophy is a critical factor in Wil’s life, and they make the most of it. Wil and Emily grew up […]

READ MORE
27 Oct
  • By Alicia Clough
  • Cause in

Recap of PTC Therapeutics Community Conference Call Re: Ataluren

          PTC Therapeutics held a community conference today regarding Ataluren.  Stuart Peltz, President and CEO, PTC Therapeutics, Inc., welcomed and thanked the community as well as provided an overview of the dispute process. The call included a Q&A session with questions that were submitted to the company in advance as well […]

READ MORE
25 Oct
  • By Alicia Clough
  • Cause in

PTC to File a Formal Dispute Resolution, Host Duchenne Community Call

Dear Duchenne Community, As you might have seen, the Office of Drug Evaluation I of the FDA provided a Complete Response Letter (CRL) for the application to market ataluren in the United States. This means that the FDA believes ataluren cannot be approved at this time. We are extremely disappointed and we strongly disagree with […]

READ MORE
25 Oct
  • By Alicia Clough
  • Cause in

PTC Therapeutics Receives Complete Response Letter for Ataluren’s NDA

PTC Therapeutics received a Complete Response Letter from the Food and Drug Administration (FDA) for Ataluren’s New Drug Application (NDA).  This means that the FDA has completed its review of the drug application and has decided it will not approve the drug. We are deeply disappointed about the FDA’s decision about Ataluren.  We look forward […]

READ MORE
06 Oct
  • By Alicia Clough
  • Cause in

CureDuchenne at World Muscle Society 2017

The 22nd International Annual Congress of the World Muscle Society took place in St Malo, between October 3 – 7, 2017. There were multiple breaking news stories on Duchenne muscular dystrophy research and development from academic groups and companies alike: Sarepta Therapeutics presented several posters on latest developments and breaking news which included: The effects […]

READ MORE
03 Oct
  • By Alicia Clough
  • Cause in

Letter to the Community from PTC Therapeutics

Dear Duchenne Community, On behalf of all of PTC, we want to thank all of you for supporting the advisory committee review of ataluren. As you know, the meeting was held last Thursday, Sept. 28th. We were pleased that we could share the scientific data from our placebo controlled trials, our long-term extension studies, and […]

READ MORE
02 Oct
  • By Alicia Clough
  • Cause in

Every Bit Matters: Nutritional Suggestions for Duchenne Patients

Leading a healthy lifestyle is something that any individual should aim towards. For those with Duchenne, making nutritional modifications has the potential to improve their overall health. Research has indicated that proper nutrition is one component that can improve the overall quality of life for a person living with Duchenne.     Seven Daily Points […]

READ MORE
29 Sep
  • By Alicia Clough
  • Cause in

Q&A with Nirmal Khadka, founder of Muscular Dystrophy Organization Nepal

CureDuchenne firmly believes in working together to help any child with Duchenne muscular dystrophy find the support they need. Duchenne is a disorder which knows no cultural, economic, or social boundaries.  This fatal genetic muscle disease affects more than 300,000 children worldwide. Especially affected are muscular dystrophy patients in Nepal, as the region lacks resources […]

READ MORE